CYCLOPHARM LTD (ASX:CYC) - Why Lung Imaging Guidelines Are Shifting Towards Technegas

Send us Fan Mail ASX Investment Opportunity - Cyclopharm Ltd (ASX:CYC) China’s leading medical bodies have now named Technegas the preferred ventilation agent for pulmonary embolism imaging, and that single line has big implications. We sit down with Cyclopharm Managing Director and CEO James McBrayer to unpack what’s driving the sudden global alignment of clinical guidelines across the US, Europe, Australia and New Zealand, and China and why it’s rare for medical guidance to call out a brand by name. We start with the fundamentals of Technegas lung imaging: how a few breaths can produce a clear map of pulmonary ventilation, and why image quality and stability matter even more as hospitals move to SPECT and 3D workflows. James also walks us through the patient safety angle, including guideline commentary on radiation dose versus CT pulmonary angiography, and why evidence based practice is pushing clinicians towards a consistent “standard of care”. From there, we dig into the business and ASX investor lens: the razor blade model of recurring consumable revenue, the acceleration in US sites after FDA approval, and how network contracts and reference hospitals drive scalable rollout. We also cover delayed sites tied to funding and facility timelines, plus the “Beyond PE” growth strategy that includes CTEPH, COPD, asthma, and pre and post surgical lung assessment. Finally, we look at how AI is reshaping lung imaging by combining CT anatomy with functional ventilation data, turning scans into measurable regional lung performance that clinicians can track over time. Subscribe for more ASX Briefs, share this episode with a mate, and leave a review with your biggest takeaway.